09:00 AM EST, 12/23/2024 (MT Newswires) -- Gain Therapeutics ( GANX ) said Monday it has received approval in Australia to start a phase 1b trial of GT-02287, the company's lead allosteric small molecule in clinical development to treat Parkinson's disease with or without a GBA1 mutation.

The main objective of the phase 1b trial is to evaluate the safety and tolerability of GT-02287 and follows the completed phase 1 study in healthy volunteers that showed it was safe, well-tolerated and increased glucocerebrosidase activity, the company said.

The company said it expects to complete enrollment for the phase 1b study to be completed in the spring of 2025 and data to be released in the middle of that year.

Shares of Gain Therapeutics ( GANX ) were up 17% in recent premarket activity.